14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
In this episode of Excellence in Training, Shawn Rogers provides some of this thoughts on working wi...
Read More >
What Happened: • On May 7, 2019, Governor Jay Inslee of Washington State signed House Bill 1607 in...
Read More >
Earlier this week, President Donald Trump signed the United States-Mexico-Canada Agreement (USMCA) I...
Read More >
The Small Business Administration issued long-awaited rules governing lender and borrower obligation...
Read More >
Last week, the National Labor Relations Board (“Board”) held that employer policies that prohibit ...
Read More >
On November 20, 2019, the Supreme Court of California announced it would review and decide whether i...
Read More >